|1.||Kim, Ikyon: 1 article (01/2016)|
|2.||Jung, Youngeun: 1 article (01/2016)|
|3.||Moon, Seong-Hee: 1 article (01/2016)|
|4.||Kim, Seong Hwan: 1 article (01/2016)|
|5.||Al Matarneh, Cristina M: 1 article (05/2015)|
|6.||Daniloaia, Teofil: 1 article (05/2015)|
|7.||Shova, Sergiu: 1 article (05/2015)|
|8.||Danac, Ramona: 1 article (05/2015)|
|9.||Balan, Mihaela: 1 article (05/2015)|
|10.||Mangalagiu, Ionel I: 1 article (05/2015)|
|1.||Colorectal Neoplasms (Colorectal Cancer)
01/01/2016 - "Synthesis, characterization and biological evaluation of anti-cancer indolizine derivatives via inhibiting β-catenin activity and activating p53."
07/01/2010 - "Synthesis and antiproliferative activity of indolizine derivatives incorporating a cyclopropylcarbonyl group against Hep-G2 cancer cell line."
03/15/2008 - "We report herein the SAR studies of a series of indole- and indolizine-glyoxylamides that demonstrate substantial in vitro anti-proliferative activities against cancer cell lines, including multidrug resistance (MDR) phenotypes. "
03/15/2008 - "Indole- and indolizine-glyoxylamides displaying cytotoxicity against multidrug resistant cancer cell lines."
12/01/1992 - "The impact of the novel chemosensitizer ((2-isopropyl-1-(4-[3-N-methyl-N-(3,4-dimethoxy-beta- phenethyl)amino]propyloxy)benzenesulfonyl))indolizine (SR33557) on the intracellular distribution of doxorubicin (DOX) within the multidrug-resistant murine P388/ADR leukemia cell line was studied by fluorescence microscopy. "
12/01/1992 - "Modulation of subcellular distribution of doxorubicin in multidrug-resistant P388/ADR mouse leukemia cells by the chemosensitizer ((2-isopropyl-1-(4-[3-N-methyl-N-(3,4-dimethoxy-beta- phenethyl)amino]propyloxy)-benzenesulfonyl))indolizine."
05/15/2015 - "The antiproliferative evaluation against a NCI 60 human tumor cell line panel, revealed that two indolizine with phenanthroline skeleton exhibit a selective and significant antitumor growth inhibitory activity against Breast Cancer (MCF7 and T-47D) and a slightly moderate activity against some forms of Leukemia, Non-Small Cell Lung Cancer, Renal Cancer and Breast Cancer (MDA-MB-468). "
|5.||Calcium Channel Blockers (Blockers, Calcium Channel)
|8.||butoprozine (L 1934)